News

Filter

Current filters:

None

8776 to 8785 of 96597 results

Apricus Biosciences closes Topotarget USA acquisition

30-12-2011

Apricus Biosciences (Nasdaq: APRI) has closed its previously-announced acquisition of Topotarget USA,…

Apricus BioscienceMergers & AcquisitionsOncologyPharmaceuticalTopotargetTotect

Spanish pharma sales down 3.1% in October

30-12-2011

Data from Spain’s Ministry of Health, Social Policy and Equality shows that, in October 2011, public…

EuropeGenericsMarkets & MarketingPharmaceuticalPricingResearch

UCB and Immunomedics amend epratuzumab accord

29-12-2011

New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

Australia’s Pharma industry economic impact up by A$1 billion

29-12-2011

The Australian pharmaceutical industry’s contribution to the economy grew by an estimated A$1 billion…

Asia-PacificMarkets & MarketingPharmaceuticalResearch

Baxter taps Momenta expertise on biosimilars

28-12-2011

In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster…

Baxter InternationalBiotechnologyGenericsLicensingMomenta PharmaceuticalsResearch

Karo Bio skyrockets on deal with Pfizer

28-12-2011

Sweden’s Karo Bio (STO: KARO) saw its shares rocket 80% to 1.67 Swedish ronor on December 24, after…

Anti-Arthritics/RheumaticsImmunologicalsKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

ViroPharma buys option to acquire Meritage Pharma

28-12-2011

ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

Bristol-Myer’s brivanib disappoints in Ph III study

28-12-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has revealed disappointing results of a Phase III trial…

Bristol-Myers SquibbbrivanibOncologyPharmaceuticalResearch

Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad

28-12-2011

Japanese drug major Eisai (TYO: 4523) says that it has re-submitted the New Drug Application (NDA) for…

Anti-viralsEisaiGilead SciencesNeurologicalperampanelPharmaceuticalQuadRegulation

8776 to 8785 of 96597 results

Back to top